ライフサイエンスコーパス: paromomycin

1 ows excellent efficacy, which is better than paromomycin.

2 te RNA in the presence of the aminoglycoside paromomycin.

3 e region of the decoding site RNA with bound paromomycin.

4 o, nip1-1 mutant cells are hypersensitive to paromomycin.

5 s to increased sensitivity to the antibiotic paromomycin.

6 ed for binding the aminoglycoside antibiotic paromomycin.

7 100 microg/mL and inhibited by 400 microg/mL paromomycin.

8 dazole, followed by eradication therapy with paromomycin.

9 e and P-site tRNAs, mRNA, and the antibiotic paromomycin.

10 tially resistant to the miscoding effects of paromomycin.

11 72(2AP) yields submicromolar EC50 values for paromomycin (0.5 +/- 0.2 microM) and neomycin B (0.6 +/-

12 shmaniasis to receive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% par

13 D4 cells/microL were treated with open-label paromomycin (1.0 g twice a day) plus azithromycin (600 m

14 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days).

15 Exposure to a high concentration of paromomycin (2 mg/ml), which caused an 8% average increa

16 A paromomycin 4',6'-diol is oxidized by the Dess-Martin pe

17 ed some 50-fold by growth in the presence of paromomycin, a known translational-error-inducing antibi

18 and increased sensitivity at 37 degrees C to paromomycin, a translational inhibitor.

19 (600 mg once a day) for 4 weeks, followed by paromomycin alone for 8 weeks.

20 f the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major disease.

21 mycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone, and 58% (95% CI, 50 to 67) for vehicl

22 cin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, or vehicle control (with the same bas

23 changes (deltaH) for protonation of the five paromomycin amino groups, as well as positive heat capac

24 MR studies provide pK(a) values for the five paromomycin amino groups, as well as the temperature dep

25 jor antileishmanials (antimony, miltefosine, paromomycin, amphotericin B, and pentamidine).

26 d for hypothetical proteins in resistance to paromomycin, amphothericin B, and pentamidine.

27 its anti-association activity was blocked by paromomycin, an inhibitor for IF3, an essential initiati

28 A paromomycin analog lacking the hydroxymethyl ring I side

29 y, conformationally constrained neomycin and paromomycin analogues designed to mimic the A-site bound

30 action between the aminoglycoside antibiotic paromomycin and a small model oligonucleotide that mimic

31 ion apparatus, including hypersensitivity to paromomycin and accumulation of halfmer polysomes.

32 , and durability of combination therapy with paromomycin and azithromycin for chronic cryptosporidios

33 the pharmacological inhibitor of translation paromomycin and exposure to heat stress and paromomycin

34 ding properties of the 2-DOS aminoglycosides paromomycin and G418 (geneticin) are compared, using bot

35 Paromomycin and G418 differ with respect to their specif

36 sitivity to translation fidelity antibiotics paromomycin and geneticin, to high salt and calcium conc

37 in solution and bound to the aminoglycosides paromomycin and gentamicin C1A have been determined.

38 in solution and bound to the aminoglycosides paromomycin and gentamicin C1a were determined previousl

39 vity to other translation inhibitors such as paromomycin and hygromycin B, which affect translation f

40 ates increased sensitivity to the antibiotic paromomycin and increased programmed -1 ribosomal frames

41 were plated in the presence of 50 microg/ml paromomycin and incubated in an anaerobic chamber.

42 effectively than the related aminoglycosides paromomycin and lividomycin A.

43 be the unsuspected major route of entry for paromomycin and may be of importance in the design and d

44 successfully treated with the combination of paromomycin and metronidazole.

45 This study characterized PK differences in paromomycin and miltefosine between 109 PKDL and 264 VL

46 increasing concentration of aminoglycosides (paromomycin and neomycin).

47 We show that differences in binding between paromomycin and ribostamycin can be probed by using an M

48 The binding of paromomycin and similar antibiotics to the oligonucleoti

49 The binding of paromomycin and similar antibiotics to the small (30S) r

50 The aminoglycosides paromomycin and streptomycin bind to the decoding center

51 icin bound to an A-site oligonucleotide, and paromomycin and streptomycin complexed to the 30S subuni

52 ere, we demonstrate that the aminoglycosides paromomycin and streptomycin inhibit A-site cleavage of

53 Furthermore, the miscoding antibiotics paromomycin and streptomycin rescue the defects in tRNA

54 or neomycin B and tobramycin, as compared to paromomycin and streptomycin, indicates differences in t

55 Paromomycin and the prion [PSI+], which reduce translati

56 We report that paromomycin and the related compound geneticin manifest

57 To facilitate the synthesis of paromomycin and/or neomycin analogues, we describe a cle

58 ith several aminoglycosides (geneticin G418, paromomycin, and hygromycin B) and the antimalarial drug

59 amount of 40 S subunits, hypersensitivity to paromomycin, and increased levels of 20 S pre-rRNA.

60 tic rRNA A-site subdomain with ribostamycin, paromomycin, and lividomycin, whereas apramycin preferen

61 des including kanamycin A and B, tobramycin, paromomycin, and neomycin B to the corresponding fully g

62 cin B and its lipid formulations, injectable paromomycin, and oral miltefosine.

63 of the aminoglycoside antibiotics neomycin, paromomycin, and ribostamycin to a RNA oligonucleotide t

64 -deoxystreptamine aminoglycosides, neomycin, paromomycin, and ribostamycin, to two different chimeric

65 Both paromomycin-Aquaphilic and the Aquaphilic vehicle were v

66 This study enlarges the potential use of 15% paromomycin-Aquaphilic from one form of Old World CL to

67 valent, aggressive form of New World CL, 15% paromomycin-aquaphilic was vastly superior to a negative

68 3-30%) for Aquaphilic vehicle (P < .0001 vs paromomycin-Aquaphilic), and 14 of 20 (70%, 95% CI 48-85

69 , 95% confidence interval [CI] 62.5-88%) for paromomycin-Aquaphilic, 2 of 20 (10%, 95% CI 3-30%) for

70 f the RNA binding affinities of neomycin and paromomycin are consistent with at least three drug NH(3

71 values associated with the free base form of paromomycin are lower in magnitude than the correspondin

72 thermodynamic information is presented using paromomycin as the model aminoglycoside.

73 ll ribosomal subunit bound to the antibiotic paromomycin at ambient temperature (3.4-A structure).

74 n contrast, the aminoglycoside-based polymer paromomycin-BGDE, enhanced adenoviral gene expression wi

75 veal the following significant features: (i) Paromomycin binding enhances the thermal stabilities of

76 In addition, the impact of paromomycin binding on both RNase H- and RNase A-mediate

77 the ribosomal electrostatic potential in the paromomycin binding site provided insight into the elect

78 (iii) Paromomycin binding to all three octamer duplexes is lin

79 (ii) Paromomycin binding to the DNA.RNA hybrid duplex induces

80 rRNA known to be important for high-affinity paromomycin binding to the ribosome.

81 The aminoglycoside antibiotic paromomycin binds specifically to an RNA oligonucleotide

82 al titration calorimetry studies reveal that paromomycin binds to the EcWT duplex with a 31-fold high

83 erioribosomal activity comparable to that of paromomycin, but is significantly more selective showing

84 binding, was observed in the prokaryotic RNA-paromomycin complex in comparison to its free form.

85 site, and the solution structure of the RNA-paromomycin complex was determined by nuclear magnetic r

86 ide antibiotics and the structure of the RNA-paromomycin complex was previously determined by nuclear

87 change is not observed in the eukaryotic RNA-paromomycin complex, disrupting the binding pocket for r

88 cently solved the structure of an A-site RNA-paromomycin complex.

89 d higher than the estimated intracytoplasmic paromomycin concentration, suggestive of host cell vesic

90 . parvum infection did not lead to increased paromomycin concentrations compared to those in uninfect

91 ent dye labeled derivative of the antibiotic paromomycin (CRP) stoichiometrically with a dissociation

92 family to high concentrations of neomycin or paromomycin decreased to a significant, nearly identical

93 er, preinfection exposure of Caco-2 cells to paromomycin did not result in subsequent inhibition of p

94 te development, indicating that if exogenous paromomycin enters the infected host cell vesicular comp

95 to their specificities of action, with only paromomycin exhibiting a specificity for prokaryotic ver

96 partially inducing these structural changes, paromomycin facilitates binding of near-cognate tRNAs.

97 osides gentamicin, amikacin, tobramycin, and paromomycin for eight premature stop codon mutations ide

98 te therapies against C. parvum and have used paromomycin for evaluation of this model.

99 (v) The observed affinity of paromomycin for the RNA.RNA and DNA.RNA duplexes decreas

100 (iv) The affinity of paromomycin for the three host duplexes follows the hier

101 the apical tip of H69 and the 6'-hydroxyl on paromomycin from within the drug's canonical h44-binding

102 paromomycin and exposure to heat stress and paromomycin functions synergistically to reduce yeast vi

103 ructures of the 80S ribosome in complex with paromomycin, geneticin (G418), gentamicin, and TC007, so

104 s trial provides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerat

105 (95% confidence interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for parom

106 The paromomycin glycosides retain activity against clinical

107 except in five patients, one in each of the paromomycin groups and three in the vehicle-control grou

108 ion-site reactions were more frequent in the paromomycin groups than in the vehicle-control group.

109 the host RNA follow the hierarchy neomycin > paromomycin > ribostamycin.

110 The sensitivity to the aminoglycoside paromomycin has been analyzed in lymphoblastoid cell lin

111 oding region A-site oligonucleotide bound to paromomycin has been determined using NMR spectroscopy a

112 n the presence and absence of the antibiotic paromomycin, have been solved at between 3.1 and 3.3 ang

113 icin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on angiogenin-induced cell p

114 omplemented the nip7-1 ts growth defect, the paromomycin hypersensitivity, and the halfmer defect.

115 of its amino groups, with the RNA binding of paromomycin I and neomycin B being linked to the protona

116 By contrast, at pH 9.0, the RNA binding of paromomycin I and neomycin B is coupled to the uptake of

117 this value being 6.92 in neomycin B, 7.07 in paromomycin I, and 7.24 in lividomycin A.

118 a) values of the amino groups in neomycin B, paromomycin I, and lividomycin A sulfate, with the resul

119 For paromomycin I, the protonation reactions involve the 1-,

120 GCN1 expression conferred sensitivity to paromomycin in a manner dependent on its ribosome bindin

121 We performed a randomized trial of 15% paromomycin in Aquaphilic (40 patients) vs Aquaphilic ve

122 Recently, 15% paromomycin in Aquaphilic, a complex base to facilitate

123 The usefulness of paromomycin in Cryptosporidium infection was shown in bo

124 second, fidelity-modulating binding site for paromomycin in the 16S ribosomal RNA that facilitates cl

125 n15 makes yeast cells extremely sensitive to paromomycin, indicating that the natural high resistance

126 Binding by the small antibiotic paromomycin induced the inactive-to-active conversion, c

127 Paromomycin induces the destacking of the base at positi

128 rporation at Ala195 GCU was not increased by paromomycin, inferring that this error did not result fr

129 Differences in the kinetic mechanism of paromomycin inhibition on stop and sense codons, paired

130 s that are essential for a high-affinity RNA-paromomycin interaction.

131 the aminoglycoside antibiotics neomycin and paromomycin is described in which ring I, involved in cr

132 poridiosis exists, though the aminoglycoside paromomycin is somewhat effective.

133 ral high resistance of the yeast ribosome to paromomycin is, in large part, due to the absence of the

134 but not the stoichiometry for the binding of paromomycin (K(d) = 2.6 +/- 0.1 microM).

135 inity for neomycin B and tobramycin than for paromomycin (K(d)s = 0.3 +/- 0.1, 0.2 +/- 0.2 and 5.4 +/

136 o 100 microg/ml chloramphenicol, gentamycin, paromomycin, lincomycin, hygromycin, and tetracycline, a

137 amycin B, tobramycin, sisomicin, neomycin B, paromomycin, lividomycin A, and ribostamycin.

138 Paromomycin modulated parasitological and clinical param

139 Aminoglycoside antibiotics, including paromomycin, neomycin and gentamicin, target a region of

140 study of interaction of the aminoglycosides paromomycin, neomycin, ribostamycin, and neamine with th

141 the other two creams but containing neither paromomycin nor gentamicin).

142 Paromomycin not only inhibited all three reactions but a

143 e aminoglycosides apramycin, gentamicin, and paromomycin on ongoing protein synthesis directly in liv

144 Exposure to a high concentration of paromomycin or neomycin caused a variable but significan

145 nced affinity of neomycin relative to either paromomycin or ribostamycin is primarily, if not entirel

146 Paromomycin (PAR), a broad-spectrum aminoglycoside antib

147 e of the Leishmania ribosome in complex with paromomycin (PAR), a highly potent compound recently app

148 ing PKDL to VL patients on the same regimen, paromomycin plasma exposures were 0.74- to 0.87-fold, wh

149 ts were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days

150 This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to s

151 s < or = 45 microM reveal that the extent of paromomycin protonation linked to the binding of the dru

152 C. reinhardtii expression vector conferring paromomycin resistance.

153 the context of a mitochondrial genome with a paromomycin-resistance allele.

154 In a paromomycin-resistant background, mss1 and mto1 mutants

155 The paromomycin-resistant colonies that formed within 3-5 da

156 Molecular analysis of paromomycin-resistant embryogenic calli and of plants re

157 icking the bound side chains of neomycin and paromomycin, respectively, show excellent activity and,

158 Further characterization of the compromised paromomycin response identified a probable second, fidel

159 Since the addition of paromomycin restores A site binding, it appears that the

160 Selection of bombarded tissue with paromomycin resulted in the establishment of putative tr

161 mpetition ESI-MS with a known A-site binder (paromomycin) revealed that peptide binding occurs near t

162 By solving the crystal structure of the paromomycin-ribosome complex, we observe specific contac

163 Neomycin, paromomycin, ribostamycin and neamine bind in the major

164 he different complexes formed with neomycin, paromomycin, ribostamycin and neamine suggest similar st

165 inoglycosides chemically related to neomycin-paromomycin, ribostamycin and neamine-each bind to sites

166 hydroxymethyl side chain of the neomycin or paromomycin ring I, as part of the dioxabicyclooctane ri

167 ear NMR and compared to the structure of the paromomycin-RNA complex.

168 e interval [CI], .41-.74) lower capacity for paromomycin saturable reabsorption in renal tubules, and

169 on how the bacterial ribosome-targeting drug paromomycin selectively inhibits the eukaryotic L. donov

170 pe of mto1 and mss1 mutants is not seen in a paromomycin-sensitive genetic background.

171 med -1 ribosomal frameshifting and conferred paromomycin sensitivity.

172 In particular, 4'-O-beta-d-xylopyranosyl paromomycin shows antibacterioribosomal activity compara

173 is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral l

174 gly, we found that growth in the presence of paromomycin stimulated luciferase activity for only a sm

175 e 30S subunit complexed with the antibiotics paromomycin, streptomycin and spectinomycin, which inter

176 scopy and compared to the prokaryotic A-site-paromomycin structure.

177 yotic rRNA sequences show reduced binding of paromomycin, suggesting a physical origin for the specie

178 e sensitive to the aminoglycoside antibiotic paromomycin than a upf1 delta strain, and frameshifting

179 ogues, we describe a cleavage of ring I from paromomycin that proceeds in the presence of azides and

180 As in the complex with paromomycin, the asymmetric internal loop is closed by a

181 For paromomycin, there is only one binding site with K(D) =

182 accompany the binding of the aminoglycoside paromomycin to both prokaryotic and eukaryotic rRNA A-si

183 Binding of aminoglycosides such as paromomycin to DIS272(2AP) results in significant fluore

184 pacity change (DeltaC(p)) for the binding of paromomycin to each rRNA A-site is near zero, with the n

185 Binding of the aminoglycoside paromomycin to the 2AP-substituted forms of EcWT and A14

186 (vi) The binding of paromomycin to the DNA.RNA hybrid duplex inhibits both R

187 e approximately 25-50-fold weaker binding of paromomycin to the eukaryotic decoding-site oligonucleot

188 nce in 16 S rRNA result in weaker binding of paromomycin to the oligonucleotide.

189 d contrast the binding of the aminoglycoside paromomycin to three octamer nucleic acid duplexes of id

190 ystallographic information from complexes of paromomycin, tobramycin, and Geneticin bound to an A-sit

191 For 30 years, 15% paromomycin topical formulations have been in clinical e

192 Global [3H]paromomycin uptake by Caco-2 cells was approximately 200

193 estimated intracytoplasmic concentrations of paromomycin, using an intracellular bacterial killing as

194 t of cryptosporidiosis with azithromycin and paromomycin was associated with significant reduction in

195 Paromomycin was covalently linked to solid support via a

196 he presence/absence of high concentration of paromomycin was observed in symptomatic or asymptomatic

197 is, respectively, occurred in North America; paromomycin was shown to be ineffective treatment for cr

198 ucleotides that are important for binding of paromomycin were identified by performing quantitative f

199 -glycosides of the aminoglycoside antibiotic paromomycin were synthesized and evaluated for their abi

200 had reduced affinity for the aminoglycoside paromomycin, whereas no discernible reduction in affinit

201 The miscoding antibiotic paromomycin, which binds the decoding center and promote

202 (ii) Eis_Msm triacetylates paromomycin, which can be only diacetylated by Eis_Mtb.

203 contrast, the aminoglycosides gentamicin and paromomycin, which interact with the decoding region of

204 inical strains of MRSA that are resistant to paromomycin, which is demonstrated to be a consequence o

205 Neomycin and paromomycin, which only differ by their ring-I 6'-polar

206 slation rates in the presence and absence of paromomycin, which reflected the effect of the drug on m

207 t readthrough with two drugs, gentamicin and paromomycin, which was confirmed by western blot and in

208 Propylamycin is a 4'-deoxy-4'-alkyl paromomycin whose alkyl substituent conveys excellent ac

209 and binding stoichiometry for tobramycin and paromomycin with a 27-nucleotide RNA construct represent

210 ystallographic information from a complex of paromomycin with the 30S subunit was used as a framework

211 3 trial of topical treatments containing 15% paromomycin, with and without 0.5% gentamicin, for cutan

212 A sites with a markedly lower affinity than paromomycin, with the affinities of both drugs for the h